Search the Newsreel

QBE Insurance Group Stock And Other High Yield ASX Dividend Picks

Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS

Lucid Diagnostics (NASDAQ:LUCD) reported a Q2 loss of $0.08 per share, missing analyst estimates by $0.04, despite revenue of $1.47 million which slightly exceeded expectations. Shares rose 1.9% following the announcement but remain near their 12-month low. Insider buying was noted, with Director Dennis …

Quest Diagnostics Keeps Quarterly Dividend at $0.86 per Share, Payable Oct. 21, to Shareholders of Record Oct. 6

Quest Diagnostics (DGX) announced that it will maintain its quarterly dividend at $0.86 per share. This dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. The announcement was published on August 12, 2026, by MT Newswires.

Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue

Lucid Diagnostics (LUCD) reported a 26.7% increase in Q2 2026 revenue, reaching $1.5 million, which slightly exceeded analyst expectations. Despite this top-line growth, the company continued to post significant losses, with a net loss of $14.7 million. Insider trading activity shows one purchase in …

$LUCD Q2 '26 Earnings Results & Recap

Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest …

Quest Diagnostics Sets Oct. 21 Date for Cash Dividend

Quest Diagnostics (NYSE: DGX) has announced a quarterly cash dividend of $0.86 per share. The dividend will be payable on October 21, 2026, to shareholders of record as of October 6, 2026. This move reflects the company's commitment to providing direct cash returns to …

Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary

Lucid Diagnostics Inc. reported its Q2 2026 financial results, showing revenue of $1.47 million and a net loss of ($14.72 million), resulting in a diluted loss per share of ($0.08). The company experienced increased EsoGuard test volume, expanded commercialization efforts, secured positive payer access …

Carriage Services (CSV) sees Vineyard Capital disclose 41,800-share 0.3% stake

Vineyard Capital Partners, L.L.C. and Jeffrey K Boutwell have filed an amended Schedule 13G, disclosing a beneficial ownership of 41,800 shares of Carriage Services Inc (CSV) common stock, which represents 0.3% of the class. Jeffrey K Boutwell, as managing member, has shared voting and …

Suraksha Diagnostic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Suraksha Diagnostic Q1 Results: Net profit up 28% YoY to ₹125.8 lakh

Scotiabank Forecasts Strong Price Appreciation for Iamgold (NYSE:IAG) Stock

Scotiabank raised its price target for Iamgold (NYSE:IAG) to $23 from $22, maintaining a "sector perform" rating and suggesting a 25.71% potential upside. Despite this, other analysts have recently lowered their targets or ratings, though the overall consensus remains a "Moderate Buy" with an …

Qiagen N.V. : DZ Bank reiterates its Buy rating

DZ Bank has reiterated its "Buy" rating for Qiagen N.V. Analyst Sven Kürten confirmed his positive recommendation for the biotechnology and medical research company. Qiagen N.V. is a global leader in providing chemical products for DNA and RNA manipulation.

CODX Q2'26 Earnings: EPS estimate is (3.00) USD

Co-Diagnostics, Inc. (CODX) is scheduled to release its Q2'26 earnings on August 13th, after market close, with an anticipated announcement time of 4:01 PM ET (8:01 PM UTC). Analysts estimate revenue for the quarter to be 132.58 thousand USD and earnings per share (EPS) …

CLEO Diagnostics (ASX:COV): Can Its Ovarian Cancer Test Become a Breakthrough Diagnostics Platform?

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Goldman Sachs Group Inc. has disclosed a 2.63% voting interest in Qiagen N.V., a Netherlands-based life sciences company, through a filing with the Dutch Authority for the Financial Markets. This stake is composed of both indirect real holdings and potential positions via various derivative …

The Manufacturers Life Insurance Company Lowers Stock Holdings in Diageo plc $DEO

The Manufacturers Life Insurance Company significantly reduced its stake in Diageo plc (NYSE:DEO) by 98.7% in the first quarter, selling over 1.3 million shares. Despite this large sale, other institutional investors have shown mixed activity, with some increasing and others purchasing new stakes in …

Vijaya Diagnost Standalone June 2026 Net Sales at Rs 218.54 crore, up 24.99% Y-o-Y

EKF Diagnostics Cancels 75,000 Shares in Targeted Buyback

Insight Molecular Diagnostics to Host Virtual KOL Event on

Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, to discuss its GraftAssure platform and the potential for in-house heart transplant rejection testing. The event will feature Dr. Max Jacob Liebo, alongside iMDx's VP of Medical Affairs and …

Doctors to discuss in-house heart transplant testing Aug. 17

Insight Molecular Diagnostics (Nasdaq: IMDX) will host a virtual Key Opinion Leader (KOL) event on August 17, 2026, to discuss its GraftAssure dd-cfDNA platform. The event will feature cardiologist Max Jacob Liebo, MD, and iMDx executives, focusing on the GraftAssureDx kit for kidney and …

Why Did CODX Stock Nearly Double In Value Today?

Co-Diagnostics (CODX) stock surged 93% after the company announced it completed the assay development strategy for the Bundibugyo strain of the Ebola virus, linked to the ongoing outbreak in the Democratic Republic of Congo and Uganda. The World Health Organization has expressed serious concerns …

IAMGOLD (IAG) nets $70M and royalty in Bambadji joint venture sale

IAMGOLD Corporation has completed the sale of its indirect 35% interest in the Bambadji Joint Venture in Senegal to Fortuna Mining Corp. for approximately $70 million in cash, before taxes and transaction costs. This divestiture monetizes a non-core exploration asset, allowing IAMGOLD to focus …

REG - Diageo PLC - Director/PDMR Shareholding

Diageo PLC announced director/PDMR shareholdings related to transactions made on August 10, 2026, under its 2001 Share Incentive Plan. Several members of the Executive Committee, including Dayalan Nayager, Randall Ingber, Ewan Andrew, Dan Mobley, and CFO Nik Jhangiani, purchased partnership shares and received matching …

Quest Diagnostics Incorporated (DGX) stock price, news, quote and history

Diageo Share Price: Fiscal 2026 Results

Diageo announced fiscal 2026 net sales of $19.6 billion, alongside a new $1 billion cost-savings plan and a $1.2 billion restructuring program under CEO Dave Lewis, causing its shares to rise. While the company guided for flat organic sales growth in fiscal 2027 and …

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Fortuna to buy Bambadji gold project in Senegal from Barrick, IAMGOLD (NYSE:FSM)

Fortuna Mining (FSM) has announced an agreement to acquire the Bambadji advanced gold exploration project in Senegal from Barrick Mining (B) and IAMGOLD (IAG) for $200 million in cash. Barrick will receive $130.35 million and IAMGOLD will receive $69.65 million from the transaction. The …

EKF Diagnostics Tightens Capital Base With Targeted Share Buyback

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake

Jane Street Group, LLC and its subsidiaries, Jane Street Capital, LLC and Jane Street Global Trading, LLC, have disclosed a 1.7% equity stake in Co-Diagnostics, Inc. (NASDAQ: CODX). This ownership amounts to 89,240 shares of common stock, held with shared voting and dispositive power. …

IAMGOLD completes sale of Senegal stake for $70 million

IAMGOLD Corporation has finalized the sale of its 35% interest in the Bambadji Joint Venture and an associated exploration permit in Senegal to Fortuna Mining Corp. The transaction generated approximately $70 million in cash proceeds for IAMGOLD before taxes and transaction costs. The company …

Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview

Lucid Diagnostics Inc is anticipated to report a loss of 7 cents per share in its upcoming earnings announcement. This preview indicates the company's expected financial performance for the period.

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …